

Docket No.: PP16502.015

Please type a plus sign (+) inside this box. FORM PTO/SB/08

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		<i>Complete if Known</i>			
		Application Number	Unassigned		
		Filing Date	Filed Herewith		
		First Named Inventor	Jia-Hwa Fang et al.		
		Group Art Unit	1615		
		Examiner Name	Unassigned		
Sheet	1	of	4	Attorney Docket Number	PP16502.015

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY
		Number	Class/Subclass		
[Signature]	1	5,538,739	424/501	Bodmer et al.	07-1996
	2	5,643,605	424/489	Cleland et al.	07-1997
	3	US 2002/0009468	424/252.1	Brayden	01-2002
	4	5,783,567	514/44	Hedley et al.	07-21-1998
	5	5,869,103	424/501	Yeh et al.	02-09-1999
	6	5,871,747	424/208.1	Gengoux-Sedlik et al.	02-16-1999
	7	3,523,907	252/316	Vrancken et al.	08-11-1970
	8	5,814,482	435/69.3	Dubensky Jr. et al.	09-29-1998
	9	5,842,723	285/49	Hartling et al.	12-01-1998
	10	5,928,647	424/196.11	Rock	07-27-1999
	11	6,015,686	435/69.1	Dubensky Jr. et al.	01-18-2000
	12	6,086,901	424/283.1	O'Hagan et al.	07-11-2000

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
		Office ²	Number	Class/ Subclass			
	1	WO	01/81609 A2	C12N 15 86		01-11-2001	X
	2	WO	94/28879	A61K 9		12-22-1994	X
	3	WO	95/24929	A61K 48		09-21-1995	X
	4	WO	96/20698	A61K 9		07-11-1996	X
	5	WO	97/02810	A61K 9		01-30-1997	X
	6	WO	98/10750	A61K 9		03-19-1998	X
	7	WO	90/14837	A61K 37 10		12-13-1990	X
	8	WO	94/15635	A61K 39 385		07-21-1994	X
	9	WO	97/38087	C12N		10-16-1997	X
	10	WO	98/33487	A61K 9 16		08-06-1998	X
	11	WO	99/18226	C12N 15 86		04-15-1999	X
	12	WO	00/06123	A61K 9 16		02-10-2000	X
Examiner Signature	Blessing Fubara				Date Considered	7-23-04	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation, if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English Language Translation is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	Unassigned
				Filing Date	Filed Herewith
				First Named Inventor	Jia-Hwa Fang et al.
				Group Art Unit	1615
				Examiner Name	Unassigned
Sheet	2	of	4	Attorney Docket Number	PP16502.015

[illegible][illegible]

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation, if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English Language Translation is attached.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Unassigned
		Filing Date	Filed Herewith
		First Named Inventor	Jia-Hwa Fang et al.
		Group Art Unit	1615
		Examiner Name	Unassigned
Sheet	3	of	4
		Attorney Docket Number	PP16502.015

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Kazzaz, J. et al., "Induction of Cytotoxic T-lymphocyte activity in mice with HIV p24 gag protein adsorbed to the surface of poly(lactide-co-glycolide) microparticles," Proceed. Int'l Symp. Control. Rel. Bioact. Mater., 26 (1999), Controlled Release Society, pp. 104-105.	X
	2	Coombes, A.G.A. et al., "Single Does, Polymeric, Microparticle-Based Vaccines: The Influence of Formulation Conditions On The Magnitude and Duration of the Immune Response To A Protein Antigen," Vaccine, Vol. 14, No. 15, 1996, pp. 1429-1438.	X
	3	Duncan, J.D. et al., "Poly(lactide-co-glycolide) Microencapsulation of Vaccines For Mucosal Immunization," Mucosal Vaccines, 1996, pp. 159-173.	X
	4	Eldridge, J. et al., "New Advances In Vaccine Delivery Systems," Seminars in Hematology, Vol. 30, No. 4, Suppl. 4, Oct. 1993, pp. 16-25.	X
	5	Higgins, D. et al., "MF59 Adjuvant Enhances the Immunogenicity of Influenza Vaccine in Both Young and Old Mice," Vaccine, Vol. 14, No. 6, 1996, pp. 478-484.	X
	6	Men, Y. et al., "Introduction of a Cytotoxic T Lymphocyte Response By Immunization With A Malaria Specific CTL Peptide Entrapped In Biodegradable Polymer Microspheres," Vaccine, Vol. 15, No. 12/13, 1997, pp. 1405-1412.	X
	7	Moore, A. et al., "Immunization With A Soluble Recombinant HIV Protein Entrapped In Biodegradable Microparticles Induces HIV-Specific CD8+ Cytotoxic T Lymphocytes And CD4+ TH1 Cells," Vaccine, Vol. 13, No. 18, 1995, pp. 1741-1995.	X
	8	Nakaoka, R. et al., "Enhanced Antibody Production Through Sustained Antigen Release From Biodegradable Granules," Journal of Controlled Release, Vol. 37 (1995), pp. 215-224.	X
	9	O'Hagan, Derek et al., "Biodegradable Microparticles for Oral Immunization, Vaccine, Vol. 11, 1993, pp. 149-154.	
	10	O'Hagan, Derek et al., "Long-Term Antibody Responses In Mice Following Subcutaneous Immunization With Ovalbumin Entrapped In Biodegradable Microparticles," Vaccine, Vol. 11, 1993, pp. 1965-1969.	
	11	Sah, H. et al., "Continuous Release of Proteins From Biodegradable Microcapsules and In Vivo Evaluation of Their Potential As A Vaccine Adjuvant," Journal of Controlled Release 35 (1995), pp.137-144.	

Examiner Signature	<i>Blessing Fubara</i>	Date Considered	7-23-04
--------------------	------------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation, if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Unassigned
				Filing Date	Filed Herewith
				First Named Inventor	Jia-Hwa Fang et al.
				Group Art Unit	1615
				Examiner Name	Unassigned
Sheet	4	of	4	Attorney Docket Number	PP16502.015

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	12	Vordermeier, H.M. et al., "Synthetic Delivery System For Tuberculosis Vaccines: Immunological Evaluation of the M. Tuberculosis 38 kDa Protein Entrapped In Biodegradable PLG Microparticles," Vaccine, Vol. 13, No. 16, 1995, pp. 1576-1582.	X	
	13	Powell, M. F. et al., "Vaccine Design: The Subunit And Adjuvant Approach," Plenum Press, New York, 1995, p.183.	X	
	14	Eldridge, J. et al., "Biodegradable and Biocompatible Poly(DL-Lactide-Co-Glycolide) Microspheres As An Adjuvant For Staphylococcal Enterotoxin B Toxoid Which Enhances The Level Of Toxin-Neutralizing Antibodies," Infection and Immunity, Vol. 59, No. 9, Sept. 1991, pp. 2978-2986.	X	
	15	Singh, Manmohan et al., "The preparation and characterization of polymeric antigen delivery systems for oral administration," Advanced Drug Delivery Reviews 34 (1998), pp. 285-304.	X	
	16	Denis-Mize, K.S. et al., "Plasmid DNA Adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells," Gene Therapy 2000, pp. 2105-2112.	X	
	17	Kazzaz, J. et al., "Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 from HIV-1," Journal of Controlled Release 67 (2000), pp. 347-356.	X	
	18	Singh, Manmohan et al., "Cationic microparticles: A potent delivery system for DNA vaccines," Proceedings of the National Academy of Science, January 18, 2000, Vol. 97, No. 2, pp. 811-816.	X	
	19	O'Hagan, Derek T., et al., "Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles," Vaccine, Vol. 11, Issue 9, 1993, pp. 965-969.	X	
	20	Hayley, Jeffery et al., "The preparation and Characterization of Poly(lactide-co-glycolide) Microparticles. II. The Entrapment of a Model Protein Using a (Water-in-Oil)-in-Water Emulsion Solvent Evaporation Technique," Pharmaceutical Research, Vol. 10, No. 3, 1993, pp. 362-368.	X	
	21	Ogawa, Yasuaki et al., "A New Technique To Efficiently Entrap Leuprolide Acetate Into Microcapsules of Polylactic Acid or Copoly (Lactic/Glycolic) Acid," Chem. Pharm. Bull., Vol. 36, 1988, pp. 1095-1103.	X	
	22	Polo, John M. et al., "Stable alphavirus packaging cell lines for Sindbis virus-and Semliki Forest virus-derived vectors," Proceedings of the National Academy of Science, Vol. 96, April 1999, pp. 4598-4603.	X	
	23	Chapman, Barbara S., "effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells," Nucleic Acids Research, Vol. 19, No. 14, pp. 3979-3986.	X	
Examiner Signature	Blessing Fubara		Date Considered	7-23-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation, if not in conformance and not considered. Include copy of this form with next communication to applicant.